SCHEMBL12876300

SCHEMBL12876300

Cc1cc(CCc2cccnc2C)cc(-c2csc(Cn3cc(C(=O)O)cn3)n2)c1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 8/20 0.36
AKT1 P31749 1/20 0.35
ALKBH1 Q13686 1/20 0.34
EIF4E P06730 1/20 0.34
EGLN1 Q9GZT9 2/20 0.33
JAK3 P52333 1/20 0.33
DHODH Q02127 1/20 0.33
KMT2A Q03164 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 2/20 0.32
ALDH1A1 P00352 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198758 0.90 ALDH1A1 (0.39) KLKB1EIF4EEGLN1KMT2AALDH1A1
SCHEMBL12875981 0.88 KLKB1 (0.41) KLKB1AKT1ALKBH1EGLN1DHODH
SCHEMBL12876201 0.87 KLKB1 (0.40) KLKB1AKT1EIF4EDHODHKMT2A
SCHEMBL12876294 0.84 RAB9A (0.36) KLKB1AKT1ALKBH1EIF4EEGLN1
SCHEMBL12875968 0.82 L3MBTL1 (0.41) KLKB1AKT1ALKBH1EGLN1DHODH
SCHEMBL12875995 0.81 ALKBH1 (0.48) KLKB1ALKBH1EGLN1KMT2AMAPT
SCHEMBL12876264 0.81 DHODH (0.34) KLKB1AKT1ALKBH1EGLN1DHODH
SCHEMBL12875682 0.78 SIRT5 (0.44) KLKB1AKT1DHODHKMT2ARAB9A
SCHEMBL12876130 0.78 KMT2A (0.37) KLKB1AKT1KMT2ARAB9A
SCHEMBL12876129 0.78 KMT2A (0.45) KLKB1ALKBH1DHODHKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A KLKB1 3765/4885AKT1 402/4885ALKBH1 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.